The Asia-Pacific Plasma Therapy Market is expected to reach $214 million by 2030 at a CAGR of 13.4% from 2023 to 2030. Platelet-rich plasma (PRP) therapy is a form of regenerative medicine. In this procedure, the growth factors in the blood, such as platelets containing plasma, are injected into the wounded site to improve new tissue growth and promote healing. This procedure is widely used in orthopedics, dermatology, ophthalmology, and others. PRP therapy promotes bone healing in osteoporosis, arthritis, and sports medicine. It is also used to rejuvenate skin, remove acne scars, treat alopecia, and promote healing of an eye injury, among other applications.
The growth of the Asia-Pacific plasma therapy market is attributed to the advantages offered by PRP treatment, the increasing awareness toward PRP therapies, the rising prevalence of musculoskeletal, sports, & orthopedic injuries, and the growing number of cosmetic procedures. In addition, increasing PRP treatments and advancing healthcare in Asia-Pacific countries will likely offer significant opportunities for platelet-rich plasma therapy providers. However, the availability of alternatives for PRP treatment and side effects associated with PRP may limit the growth of the platelet-rich plasma (PRP) therapy market to some extent during the forecast period.
Platelet-rich plasma (PRP) treatment is a non-surgical, negligibly obtrusive method that can help treat various conditions. PRP treatment can be useful in decreasing or wiping out torment, diminishing the requirement for prescriptions, and improving the personal satisfaction of someone experiencing ceaseless torment or diminished capacity. PRP therapy is among the cutting-edge approaches that have significantly helped enhance the healing process for most soft tissue damages and musculoskeletal injuries.
PRP treatment is a promising therapy in reversing joint damage and eliminating disease progression among patients suffering from knee osteoarthritis and is effective for relieving chronic lower back pain. Platelet-rich plasma therapy is beneficial in terms of various cosmetic applications. PRP therapy is completely natural, making it ideal for various cosmetic purposes, including hair loss, acne scarring, fine lines treatment, rejuvenation of tired eyes, and long-term effect. The PRP facial helps to stimulate the body’s collagen production rate in people dealing with skin trauma. Moreover, the therapy enhances skin tone and texture, providing tighter and firmer skin.
Additionally, PRP therapy is an imperceptible obtrusive therapy, which acts as a non-surgical method. The PRP treatment also leaves no scars, as no cuts are made during the procedure. The procedure is helpful in post-surgical healing and treating tendon, ligament, muscle, and joint injuries. Hence, the advantages offered by PRP treatment in various medical applications will likely augment the growth of the platelet-rich plasma therapy market.
Click here to: Get a Free Sample Copy of this Report
Regenerative medicine, including PRP therapies, is emerging as a practical medicine for various illnesses. The significant advantages offered by the medicine have led to its increasing adoption. Recent years have witnessed an increasing awareness among the common populace regarding the availability of PRP therapies due to the benefits offered by the treatment in varied medical streams, including dental, cosmetic, orthopedic, and others. PRP therapy has gained popularity over the years. This accounts for the number of advanced science and clinical studies and increasing public awareness towards the use of the therapy.
PRP injections have become popular recently, particularly for treating sports-associated musculoskeletal injuries. Moreover, the easy availability of these injections among private and public hospitals and clinics in North America & Europe has further contributed to its growing awareness.
Furthermore, popular media coverage of the new and emerging biotechnology therapies, including PRP treatments, has also helped reach the common populace. The rising use of PRP injections by athletes and celebrities has promoted the use of regenerative therapies, thereby leading to the market's growth.
Key Findings of the Asia-Pacific Plasma Therapy Market Study:
In 2023, the Pure PRP Segment is Expected to Dominate this Market
Based on type, the Asia-Pacific plasma therapy market is segmented into pure PRP, leukocyte–rich PRP, pure platelet-rich fibrin, and leukocyte and platelet-rich fibrin. In 2023, the pure PRP segment is expected to account for the largest share of the market. Pure PRP is preferred as it is autologous and has little to no risk of allergic or immune reaction. In addition, the probability of side effects using pure autologous PRP is much less, contributing to the largest share of the segment. Furthermore, pure PRP is also advantageous over conventional PRP in many applications, such as torn tendons, tendinitis, muscle injuries, arthritis-related pain, joint injuries, hair loss, and others.
In 2023, the Orthopedics & Traumatology Segment is Expected to Account for the Largest Share of the Market
Based on application, the Asia-Pacific plasma therapy market is segmented into orthopedics & traumatology, rheumatology, dermatology and cosmetology, ophthalmology, stomatology and odontology, and other applications. In 2023, the orthopedics & traumatology segment is expected to account for the largest share of the market. The high incidence of musculoskeletal injuries disorders like fractures and the high bone injury rate contributes to the largest share of the segment. For instance, according to the International Osteoporosis Foundation, it is projected that by 2050, 50% of all osteoporotic hip fractures will occur in Asia. Additionally, Various conferences are being conducted worldwide for sharing and discussing the importance of PRP in orthopedic applications, which is also expected to contribute to the segment growth. For instance, in September 2022, Biobridge Foundation conducted the 2nd Biobridge Asia-Pacific conference in Thailand to use PRP as a modality in musculoskeletal/orthopedics.
In 2023, the Hospitals & Clinics Segment is Expected to Account for the Largest Share of this Market
Based on end user, the Asia-Pacific plasma therapy market is segmented into hospitals & clinics and research institutes. In 2023, the hospitals & clinics segment is expected to account for the largest share of the market. The largest share of the segment is attributed to the rise in healthcare spending and increasing awareness and prescriptions for PRP treatments and procedures for patients with various medical conditions. Additionally, cosmetic and plastic surgeries are gaining popularity in recent years as procedures, and treatments are easily accessible and enhance individuals’ appearance. Cosmetic tourism in Asia-Pacific is also increasing, positively impacting the market growth. For instance, according to the Ministry of Health and Welfare, in South Korea, the number of medical tourists for cosmetic surgery and medical tourism increased by 70.1% in 2022 from 2021, of which 15.8% of tourists visited for plastic surgery. PRP therapy is gaining more traction in cosmetic clinics to boost facial rejuvenation and faster healing from scars and plastic surgeries.
Japan: Fastest Growing Country Market
Japan is expected to register the highest CAGR during the forecast period. Conferences promoting the use of PRP and growth in the geriatric population are factors driving the market growth in Japan. Moreover, the decline in the fertility rate is further expected to create growth opportunities for the increasing adoption of PRP therapies in the country. The initiatives by different organizations to set up conferences and workshops promoting the use of PRP are expected to have a positive impact on the market in Japan. For instance, in May 2023, the event organizer Magnus Group Ltd (U.K.) held an International Conference on Dermatology and Cosmetology in Tokyo, Japan. The conference discussed the positive results of PRP from clinical studies for aging. Such conferences promoting the use of PRP for dermatological applications are expected to promote market growth in Japan.
Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past few years. The key players operating in the Asia-Pacific plasma therapy market are Arthrex, Inc. (U.S.) DePuy Synthesis, Inc. (Johnson & Johnson) (U.S.), Global Stem Cells Group, Inc.(U.S.), Terumo Corporation (Japan), Regen Lab SA (Switzerland), Stryker Corporation (U.S.) Zimmer Biomet Holdings, Inc. (U.S.), Exactech Inc. (U.S.), Beijing Manson Technology Co., Ltd. (China), Alocuro (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A.(Spain), Octapharma AG (Switzerland), and CSL Limited (Australia).
Scope of the Report:
Asia-Pacific Plasma Therapy Market Assessment, by Type
Asia-Pacific Plasma Therapy Market Assessment, by Application
Asia-Pacific Plasma Therapy Market Assessment, by End User
Asia-Pacific Plasma Therapy Market Assessment , by Country
Key questions answered in the report:
The Asia-Pacific plasma therapy market studies different types and applications of plasma therapy. The Asia-Pacific plasma therapy market studied in this report involves the analysis of various segments at country levels.
The Asia-Pacific plasma therapy market is projected to reach $214 million by 2030 at a CAGR of 13.4% from 2023 to 2030.
Among all the types, studied in the report pure PRP segment is expected to account for the largest share of the market in 2023. The largest share of the segment is attributed to pure PRP is preferred as it is autologous, and there is little to no risk of any allergic or immune reaction.
The growth of the Asia-Pacific plasma therapy market is attributed to the advantages offered by PRP treatment; increasing awareness toward PRP therapies; the rising prevalence of musculoskeletal, sports, & orthopedic injuries; and the growing number of cosmetic procedures. In addition, increasing PRP treatments and advancing healthcare in Asia-Pacific countries will likely offer significant opportunities for platelet-rich plasma therapy providers.
The key players operating in the Asia-Pacific plasma therapy market are Arthrex, Inc. (U.S.) DePuy Synthesis, Inc. (Johnson & Johnson) (U.S.), Global Stem Cells Group, Inc.(U.S.), Terumo Corporation (Japan), Regen Lab SA (Switzerland), Stryker Corporation (U.S.) Zimmer Biomet Holdings, Inc. (U.S.), Exactech Inc. (U.S.), Beijing Manson Technology Co., Ltd. (China), Alocuro (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A.(Spain), Octapharma AG (Switzerland), and CSL Limited (Australia).
Japan is expected to register the highest CAGR during the forecast period. Conferences promoting the use of PRP and growth in the geriatric population are the factors driving the market growth in Japan.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Advantages Offered by PRP Treatment
4.2.2. Increasing Awareness Toward PRP Therapies
4.2.3. Rising Prevalence of Musculoskeletal and Sports Injuries
4.2.4. Growing Number of Cosmetic Procedures
4.3. Restraints
4.3.1. Availability of Alternatives for PRP Treatment
4.3.2. Side-effects Associated with the Use of PRP
4.4. Opportunities
4.4.1. Increasing Applications of PRP Treatments
4.4.2 Advancing Healthcare in Emerging Economies
4.5. Challenges
4.5.1. Stringent Regulatory Framework for the Use of PRP
4.6. Trends
4.6.1 Current Indications/Applications of PRP Therapy
4.6.2. Upcoming/Future Indications/Applications for PRP Therapy
4.7. Factor Analysis
4.8. PRP Qualification Criteria
4.9. Regulatory Analysis
4.10. Porter’s 5 Force Analysis
5. Asia-Pacific Plasma Therapy Market Assessment—by Type
5.1. Overview
5.2. Pure PRP
5.3. Leukocyte-rich PRP
5.4. Pure Platelet-rich Fibrin
5.5. Leukocyte and Platelet-rich Fibrin (L-PRF)
6. Asia-Pacific Plasma Therapy Market Assessment—by Application
6.1. Overview
6.2. Orthopedics & Traumatology
6.3. Rheumatology
6.4. Dermatology & Cosmetology
6.5. Ophthalmology
6.6. Stomatology & Odontology
6.7. Other Applications
7. Asia-Pacific Plasma Therapy Market Assessment—by End User
7.1. Overview
7.2. Hospitals & Clinics
7.3. Research Institutes
8. Asia-Pacific Plasma Therapy Market Assessment –by Country
8.1. Overview
8.2. China
8.3. Japan
8.4. India
8.5. South Korea
8.6. Australia
8.7. Singapore
8.8. Rest of Asia Pacific
9. Competition Analysis
9.1. Introduction
9.2. Key Growth Strategies
9.3. Competitive Dashboard
9.3.1. Industry Leaders
9.3.2. Market Differentiators
9.3.3. Vanguards
9.3.4. Emerging Companies
9.4. Vendor Market Positioning
9.5. Market Share Analysis/Market Ranking, by Key Players (2022)
10. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, Strategic Developments, SWOT Analysis)
10.1. Arthrex, Inc.
10.2. DePuy Synthesis, Inc. (Johnson & Johnson)
10.3. Global Stem Cells Group, Inc.
10.4. Terumo Corporation
10.5. Regen Lab SA
10.6. Stryker Corporation
10.7. Zimmer Biomet Holdings, Inc.
10.8. Exactech Inc.
10.9. Beijing Manson Technology Co., Ltd.
10.10. Alocuro
10.11. Takeda Pharmaceutical Company Limited
10.12. Grifols, S.A.
10.13. Octapharma AG
10.14. CSL Limited
(Note: SWOT analysis is provided for the leading 5 companies.)
11. Appendix
11.1. Available Customization
11.2. Related Reports
List of Tables
Table 1 Asia-Pacific Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 2 Asia-Pacific Pure PRP Market, by Country/Region, 2021–2030 (USD Million)
Table 3 Asia-Pacific Leukocyte-rich PRP Market, by Country/Region, 2021–2030 (USD Million)
Table 4 Asia-Pacific Pure Platelet-rich Fibrin Market, by Country/Region, 2021–2030 (USD Million)
Table 5 Asia-Pacific Leukocyte and Platelet-rich Fibrin Market, by Country/Region, 2021–2030 (USD Million)
Table 6 Asia-Pacific Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 7 Asia-Pacific Plasma Therapy Market for Orthopedics & Traumatology, by Country/Region, 2021–2030 (USD Million)
Table 8 Asia-Pacific Plasma Therapy Market for Rheumatology, by Country, 2021–2030 (USD Million)
Table 9 Asia-Pacific Plasma Therapy Market for Dermatology & Cosmetology, by Country/Region, 2021–2030 (USD Million)
Table 10 Asia-Pacific Plasma Therapy Market for Ophthalmology, by Country/Region, 2021–2030 (USD Million)
Table 11 Asia-Pacific Plasma Therapy Market for Stomatology & Odontology, by Country/Region, 2021–2030 (USD Million)
Table 12 Asia-Pacific Plasma Therapy Market for Other Applications, by Country/Region, 2021–2030 (USD Million)
Table 13 Asia-Pacific Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 14 Asia-Pacific Plasma Therapy Market for Hospitals & Clinics, by Country/Region, 2021–2030 (USD Million)
Table 15 Asia-Pacific Plasma Therapy Market for Research Institutes, by Country/Region, 2021–2030 (USD Million
Table 16 Asia-Pacific Plasma Therapy Market, by Country/Region. 2021-2030 (USD Million)
Table 17 Asia-Pacific: Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 18 Asia-Pacific: Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 19 Asia-Pacific: Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 20 China: Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 21 China: Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 22 China: Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 23 Japan: Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 24 Japan: Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 25 Japan: Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 26 India: Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 27 India: Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 28 India: Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 29 South Korea: Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 30 South Korea: Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 31 South Korea: Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 32 Australia: Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 33 Australia: Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 34 Australia: Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 35 Singapore: Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 36 Singapore: Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 37 Singapore: Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 38 Rest of Asia-Pacific: Plasma Therapy Market, by Type, 2021–2030 (USD Million)
Table 39 Rest of Asia-Pacific: Plasma Therapy Market, by Application, 2021–2030 (USD Million)
Table 40 Rest of Asia-Pacific: Plasma Therapy Market, by End User, 2021–2030 (USD Million)
Table 41 Recent Developments, by Company, 2020—2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Asia-Pacific Plasma Therapy Market, by Type, 2023 VS. 2030 (USD Million)
Figure 8 Asia-Pacific Plasma Therapy Market, by Application, 2023 VS. 2030 (USD Million)
Figure 9 Asia-Pacific Plasma Therapy Market, by End User, 2023 VS. 2030 (USD Million)
Figure 10 Asia-Pacific Plasma Therapy Market, by Country/Region, 2023 VS. 2030 (USD Million)
Figure 11 Asia-Pacific Plasma Therapy Market, by Type, 2023 VS. 2030 (USD Million)
Figure 12 Asia-Pacific Plasma Therapy Market, by Application, 2023 VS. 2030 (USD Million
Figure 13 Asia-Pacific Plasma Therapy Market, by End User, 2023 VS. 2030 (USD Million)
Figure 14 Asia-Pacific Plasma Therapy Market, by Country/Region, 2023 VS. 2030 (USD Million)
Figure 15 Asia-Pacific Plasma Therapy Market Snapshot
Figure 16 Key Growth Strategies Adopted by Leading Players, 2020—2023
Figure 17 Asia-Pacific Plasma Therapy Market: Competitive Dashboard
Figure 18 Asia-Pacific Plasma Therapy Market t: Competitive Benchmarking, by Type
Figure 19 Asia-Pacific Plasma Therapy Market: Market Share Analysis (2022)
Figure 20 DePuy Synthesis, Inc. (Johnson & Johnson).: Financial Snapshot (2022)
Figure 21 Terumo Corporation: Financial Snapshot (2022)
Figure 22 Stryker Corporation: Financial Snapshot (2022)
Figure 23 Zimmer Biomet Holdings, Inc.: Financial Snapshot (2022)
Figure 24 Takeda Pharmaceutical Company Limited: Financial Snapshot (2022)
Figure 25 Grifols, S.A.: Financial Snapshot (2022)
Figure 26 Octapharma AG: Financial Snapshot (2022)
Figure 27 CSL Limited: Financial Snapshot (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Nov-2023
Published Date: Nov-2023
Published Date: Nov-2023
Published Date: Nov-2023
Published Date: Oct-2023
